Literature DB >> 11094120

18F-fluorodopa PET study of striatal dopamine uptake in the diagnosis of dementia with Lewy bodies.

X S Hu1, N Okamura, H Arai, M Higuchi, T Matsui, M Tashiro, M Shinkawa, M Itoh, T Ido, H Sasaki.   

Abstract

Using (18)F-fluorodopa PET and a constant 0.0062 influx rate in the putamen, dementia with Lewy bodies (n = 7) was distinguished from AD (n = 10) with a sensitivity of 86% and a specificity of 100%. A constant 0.0071 influx rate in the caudate yielded a sensitivity of 71% and a specificity of 100% for distinction of the two disorders. Despite a limited sample size, these findings suggest that assessing nigrostriatal dopaminergic function with (18)F-fluorodopa PET may be a useful diagnostic aid in cases of dementia with Lewy bodies while patients are alive.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11094120     DOI: 10.1212/wnl.55.10.1575

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  18 in total

1.  Assessment of CSF homovanillic acid levels distinguishes dementia with Lewy bodies from Alzheimer's disease.

Authors:  Kazutomi Kanemaru; Hiroshi Yamanouchi
Journal:  J Neurol       Date:  2002-08       Impact factor: 4.849

Review 2.  Imaging of the dopaminergic system in differential diagnosis of dementia.

Authors:  Klaus Tatsch
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-03       Impact factor: 9.236

Review 3.  PET/CT in diagnosis of dementia.

Authors:  Valentina Berti; Alberto Pupi; Lisa Mosconi
Journal:  Ann N Y Acad Sci       Date:  2011-06       Impact factor: 5.691

4.  UPDATE ON DEMENTIA WITH LEWY BODIES.

Authors:  Stella Karantzoulis; James E Galvin
Journal:  Curr Transl Geriatr Exp Gerontol Rep       Date:  2013-09-01

5.  Diffuse Lewy Body Disease.

Authors:  Theresa A. Zesiewicz; Matthew J. Baker; Peter B. Dunne; Robert A. Hauser
Journal:  Curr Treat Options Neurol       Date:  2001-11       Impact factor: 3.598

6.  Fully automatic differential diagnosis system for dementia with Lewy bodies and Alzheimer's disease using FDG-PET and 3D-SSP.

Authors:  Atsushi K Kono; Kazunari Ishii; Keitaro Sofue; Naokazu Miyamoto; Setsu Sakamoto; Etsuro Mori
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-02-22       Impact factor: 9.236

7.  Amnestic mild cognitive impairment with low myocardial metaiodobenzylguanidine uptake.

Authors:  Ryuji Sakakibara; Takeshi Ogata; Masayuki Haruta; Masahiko Kishi; Yohei Tsuyusaki; Akihiko Tateno; Fuyuki Tateno; Takayuki Mouri
Journal:  Am J Neurodegener Dis       Date:  2012-07-23

8.  Differentiation of dementia with Lewy bodies from Alzheimer's disease using a dopaminergic presynaptic ligand.

Authors:  Z Walker; D C Costa; R W H Walker; K Shaw; S Gacinovic; T Stevens; G Livingston; P Ince; I G McKeith; C L E Katona
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-08       Impact factor: 10.154

9.  Lewy body dementia and Parkinson's disease with dementia.

Authors:  Richard Dodel; Ilona Csoti; Georg Ebersbach; Gerd Fuchs; Matthias Hahne; Wilfried Kuhn; Matthias Oechsner; Wolfgang Jost; Heinz Reichmann; Jörg B Schulz
Journal:  J Neurol       Date:  2008-09       Impact factor: 4.849

Review 10.  Neuroimaging in aging and neurologic diseases.

Authors:  Shannon L Risacher; Andrew J Saykin
Journal:  Handb Clin Neurol       Date:  2019
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.